Wolfe Research initiated coverage of Abivax (ABVX) with an Outperform rating and $176 price target The company’s odds of success in Crohn’s disease may be higher than that of ulcerative colitis, the analyst tells investors in a research note. The firm says that with ulcerative colitis already succeeding, and with obefazimod having a better mechanism for Crohn’s disease, the Crohn’s readout is a better catalyst in 2026.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ABVX:
- Abivax announces patient-reported outcomes from ABTECT trial
- Abivax initiated with an Overweight at Barclays
- Abivax price target raised, named a ‘Best Idea’ at Guggenheim
- Abivax price target raised to $120 from $112 at BTIG
- Abivax’s Obefazimod: Promising Clinical Results and Market Potential Drive Buy Rating